Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial
1. Retatrutide met all major Phase 3 endpoints, delivering substantial reductions in both A1C and body weight in patients with ...
Tag: Retatrutide
#VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity
In the phase 2 clinical trial of Eli Lilly's retatrutide, the drug showed a notable weight reduction effect, with an ...
Retatrutide effectively reduces body weight in patients with obesity
1. In this randomized controlled trial, the triple-hormone-receptor agonist retatrutide was superior to placebo in reducing body weight among patients ...
Retatrutide associated with improved glycemic control and bodyweight reduction in type 2 diabetes
1. HbA1c and bodyweight reduction were greater in the retatrutide group compared to dulaglutide and placebo. 2. The effect of ...
